Publication date: 28/06/2018
As an integral part of the Multiannual Financial Framework for 2021-2027, the European Commission has outlined the budget and structure for the 9th Framework Programme, Horizon Europe, which is said to be the most ambitious Research and Innovation Programme to date.
Horizon Europe’s Budget
While the overall long-term EU budget is set to be agreed upon in 2019, the proposal for the R&D and Innovation Programme has not only been given a face, Horizon Europe, but also a body. The proposed €100 billion programme is divided into three pillars – open science, global challenges and industrial competitiveness, and open innovation.
A short breakdown:
Next to these overarching pillars, €2.1 billion is to be spent on poorer-performing EU countries (to share excellence and to reform and enhance the research and innovation system), €3.5 billion is set aside for a new investment fund (InvestEU) governed by the European Investment Bank and €2.4 billion is going to Euratom nuclear research - totaling the €100 billion budget for the Framework Programme.
While building on the success factors of previous programmes, the Commission has introduced several new features:
Horizon 2020 is one of Europe's biggest success stories. The new Horizon Europe programme aims even higher. As part of this, we want to increase funding for the European Research Council to strengthen the EU's global scientific leadership, and reengage citizens by setting ambitious new missions for EU research. We are also proposing a new European Innovation Council to modernise funding for ground-breaking innovation in Europe.
Carlos Moedas – Commissioner for Research, Science and Innovation
The Commission has clearly sought a middle ground between evolution and revolution. Carlos Moedas’ statement emphasizes the increase of funding and the modernization of structures. It’s a pragmatic answer to earlier calls from stakeholders to simplify the access to grants and to increase the budget significantly (a budget plan of 160 billion was on the table).
The proposal has fueled new discussions on how the EU should organize its research and innovation infrastructure in order to:
Like all EU decisions, this proposal will be the subject of several negotiation rounds and will need unanimous agreement from the EU’s member countries and consent from the Parliament before final adoption.
We keep a close eye on any further developments and we will send updates as soon as they are available!
What CMAST can offer
Perception of this proposal is a key factor to analyze the future output of this programme. At CMAST, we aim to bridge the values of all relevant stakeholders and foster research and innovation by offering consultancy, project management and tangible business solutions in a portfolio of areas.
Additionally, we can support you in establishing EU consortia and applying for grants.
CMAST is a leading consultancy and project management company in life sciences.
With a team of more than 90 industry experts, CMAST provides support to pharma and life sciences companies, universities and research institutes.
The company offers consultancy, project management and tangible business solutions in the following areas:
CMAST is headquartered in Temse (Belgium) and has branches in Germany, Poland and the US. Since 2018 CMAST is part of Modis Life Sciences, a subdivision of The Adecco Group, which gives the company a global reach.
More info on https://www.cmast.be